APMAdvances in Precision Medicine2424-85922424-9106Bio-Byword Scientific Publishing Pty. Ltd.10.26689/APM.v11i6.15123ArticleEvaluation of the Clinical Efficacy of Empagliflozin Combined with Levosimendan in the Treatment of Patients with Coronary Heart Disease and Heart Failurehttps://artdesignp.com/journal/APM/11/6/10.26689/APM.v11i6.15123GuoJuan20261162026-06-26Objective: To explore the effectiveness of empagliflozin + levosimendan in the treatment of coronary heart disease and heart failure. Methods: 78 patients with coronary heart disease and heart failure who visited the hospital from August 2024 to August 2025 were selected and divided into groups using a random number table, with 39 cases in each group. The control group received levosimendan treatment, and the observation group received empagliflozin combined with levosimendan treatment. The efficacy of the two groups was compared. Results: After completing treatment, the cardiac output and left ventricular ejection fraction of the observation group were higher than those of the control group, and the level of N-terminal pro-B-type natriuretic peptide was significantly lower (P < 0.05); the six-minute walking distance of the observation group was longer than that of the control group, and their exercise tolerance was better (P < 0.05); Observation: The tumor necrosis factor-α, high-sensitivity C-reactive protein, interleukin-1β, type I collagen, connective tissue growth factor, and α-smooth muscle actin in the group were lower than those in the control group (P < 0.05); the total incidence of adverse reactions was compared between the two groups (P > 0.05). Conclusion: Empagliflozin combined with levosimendan in the treatment of coronary heart disease and heart failure can improve cardiac function, reduce inflammation, delay myocardial fibrosis, and improve exercise tolerance, with good safety.Coronary heart disease,Heart Failure,Empagliflozin,Levosimendan

[1] Zhang JF, Si XC, Zhang J, et al., 2025, Effects of Empagliflozin Combined with Levosimendan on Plasma Collagen I, CTGF, and αSMA Levels in Patients with Coronary Heart Disease and Heart Failure. Journal of Cardiovascular Rehabilitation Medicine, 34(3): 344–350. [2] Fan XX, Lei YQ, Deng N, et al., 2025, Retrospective Study on the Therapeutic Effect of Levosimendan in Patients with Left Heart Failure and Pulmonary Hypertension. Heart Journal, 37(3): 291–296 + 309. [3] Hu Y, Jiang Q, Xie Z, 2025, Effects of Empagliflozin Combined with Metoprolol Treatment on Prealbumin, Cardiac Enzymes and Ventricular Remodeling in Patients with Coronary Heart Disease and Heart Failure. Journal of North Sichuan Medical College, 40(5): 581–584. [4] Liu X, Kuang XF, Yang Y, et al., 2025, Effects on Glucose Metabolism and Cardiac Function of Empagliflozin in the Treatment of Elderly Patients with Type 2 Diabetes and Coronary Heart Disease. Gerontology and Health Care, 31(3): 705–709. [5] Chinese Medical Association Cardiovascular Disease Branch, Cardiac Prevention and Rehabilitation Professional Committee of Chinese Association of Rehabilitation Medicine, Cardiac Professional Committee of Chinese Gerontology and Geriatrics Society, et al., 2023, Grassroots Version of the Chinese Guidelines for the Primary Prevention of Cardiovascular Disease. Chinese Journal of Cardiovascular Disease, 51(4): 343–363. [6] Bie HH, Qi QX, Ma XZ, et al., 2025, Efficacy of Empagliflozin Combined with SacubitrilValsartan in the Treatment of Coronary Heart Disease Complicated with HFmrEF and Its Impact on Cardiac Structure, Cardiac Function and Inflammatory Factors. Hainan Medicine, 36(8): 1082–1086. [7] Liu XC, Su GB, Zhou CY, et al., 2024, Analysis of Levosimendan Combined with Xinmailong on the Detection of Serum VEGF, TGFβ, and NTproBNP in Patients with Coronary Heart Disease and Heart Failure. Experimental and Laboratory Medicine, 42(1): 109–112. [8] Zhou J, Yan LY, 2025, Effects of Levosimendan Combined with Neoactivin on Serum NTproBNP and NE Levels in Patients with Acute Heart Failure. Liaoning Medical Journal, 39(1): 11–14.